mTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia.

Lauren M Paolella, Sarmistha Mukherjee, Cassie M Tran, Bruna Bellaver, Mindy Hugo, Timothy S Luongo, Swapnil V Shewale, Wenyun Lu, Karthikeyani Chellappa, Joseph A Baur

Molecular metabolism 2020 Feb

filter terms:

Pharmacological agents targeting the mTOR complexes are used clinically as immunosuppressants and anticancer agents and can extend the lifespan of model organisms. An undesirable side effect of these drugs is hyperlipidemia. Although multiple roles have been described for mTOR complex 1 (mTORC1) in lipid metabolism, the etiology of hyperlipidemia remains incompletely understood. The objective of this study was to determine the influence of adipocyte mTORC1 signaling in systemic lipid homeostasis in vivo. We characterized systemic lipid metabolism in mice lacking the mTORC1 subunit Raptor (RaptoraKO), the key lipolytic enzyme ATGL (ATGLaKO), or both (ATGL-RaptoraKO) in their adipocytes. Mice lacking mTORC1 activity in their adipocytes failed to completely suppress lipolysis in the fed state and displayed prominent hypertriglyceridemia and hypercholesterolemia. Blocking lipolysis in their adipose tissue restored normal levels of triglycerides and cholesterol in the fed state as well as the ability to clear triglycerides in an oral fat tolerance test. Unsuppressed adipose lipolysis in the fed state interferes with triglyceride clearance and contributes to hyperlipidemia. Adipose tissue mTORC1 activity is necessary for appropriate suppression of lipolysis and for the maintenance of systemic lipid homeostasis. Copyright © 2019 The Authors. Published by Elsevier GmbH.. All rights reserved.

Citation

Lauren M Paolella, Sarmistha Mukherjee, Cassie M Tran, Bruna Bellaver, Mindy Hugo, Timothy S Luongo, Swapnil V Shewale, Wenyun Lu, Karthikeyani Chellappa, Joseph A Baur. mTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia. Molecular metabolism. 2020 Feb;32:136-147